Publication

Video

Supplements and Featured Publications

BTK Inhibitors in B-Cell Lymphomas
Volume1
Issue 1

Dr. Tam on Varying BTK Inhibitors in Mantle Cell Lymphoma

Constantine S. Tam, MD, MBBS, discusses a comparison of BTK inhibitors in mantle cell lymphoma.

Constantine S. Tam, MD, MBBS, associate professor, Peter MacCallum Cancer Centre, compares BTK inhibitors in mantle cell lymphoma (MCL).

For example, zanubrutinib in clinical use appears to have better tolerability compared with other BTK inhibitors, such as ibrutinib, explains Tam. Ongoing studies in other hematologic malignancies will further showcase the efficacy and safety of zanubrutinib in comparison to other BTK inhibitors.

The complete remission rates for zanubrutinib are encouraging, according to Tam, but since outcomes of zanubrutinib are being reported in 2 separate studies, it is difficult to compare definitively. Tam looks forward to seeing the long-term follow-up of zanubrutinib.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity